References: Octapharma announces availability of Balfaxar ® for warfarin reversal in urgent surgery & invasive procedures. News release. Octapharma. January 3, 2024. https://www.prnewswire.com ...

Anticoagulation reversal agents are an antidote to some, but not all, DOACs The conventional method of reversing warfarin-induced major bleeds was fresh frozen plasma (FFP).

Octapharma's prothrombin complex concentrate, Balfaxar®, receives FDA approval for warfarin reversal in urgent surgery & invasive procedures. Yankee Public Relations. Funder ...

Reversal If bad mechanism, still consider FFP to reverse and/or vitamin K, even if CT negative. In a survey of trauma surgeons by Coimbra, 74% of respondents reverse warfarin.

More than 2.4 million people in the United States use warfarin to keep their blood from clotting after a heart attack, ... Octapharma secures FDA nod for warfarin reversal agent Balfaxar.

(2002). Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. British Journal of Haematology. 116:619-624. A third ...

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) is now available ...

According to the company, the medication works to replenish deficient clotting factors due to warfarin therapy, ultimately restoring blood coagulation. “The FDA approval of Balfaxar® establishes a new ...

PARAMUS, N.J., Aug. 13, 2024 /PRNewswire/ -- Octapharma USA announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar® (prothrombin complex concentrate ...

The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can ...

Octapharma is Committed to Supplying Hospitals and Medical Providers with New Prothrombin Complex Concentrate PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar ...

PARAMUS, N.J., Aug. 13, 2024 /PRNewswire/ -- Octapharma USA announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar® (prothrombin complex concentrate ...